Zollinger‑Ellison syndrome (malignant) - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Malignant) – Comprehensive Medical Guide

Zollinger‑Ellison Syndrome (Malignant)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by gastrin‑producing neuroendocrine tumors (NETs) called gastrinomas. When these tumors are malignant (i.e., they have spread beyond the pancreas or duodenum), the condition is referred to as malignant Zollinger‑Ellison syndrome. The excess gastrin stimulates the stomach lining to produce massive amounts of acid, leading to severe peptic ulcer disease, diarrhea, and malabsorption.

  • Incidence: Approximately 0.1–1 case per million people per year worldwide.1
  • Malignancy rate: About 20–30 % of gastrinomas are malignant at diagnosis; this rises to 50–70 % when tumors are >2 cm or located outside the duodenum/pancreas.2
  • Age & gender: Most patients are diagnosed between 30–60 years; slight male predominance (≈55 %).
  • Associated conditions: 20–25 % of cases occur as part of the hereditary MEN‑1 syndrome (multiple endocrine neoplasia type 1).

Symptoms

Symptoms result from hyperacidic gastric secretions and tumor spread. They can vary in severity and may mimic common gastrointestinal disorders.

  • Refractory peptic ulcer disease: Ulcers in the duodenum, jejunum, or stomach that do not heal with standard therapy.
  • Abdominal pain: Burning or gnawing pain, often worsened by meals.
  • Diarrhea: Frequent, watery stools (often >4 times/day) caused by acid‑induced inactivation of pancreatic enzymes.
  • Steatorrhea (fatty stools): Resulting from malabsorption of fat.
  • Weight loss: Due to malabsorption, chronic diarrhea, and decreased appetite.
  • Nausea & vomiting: May be related to ulcer complications or gastric outlet obstruction.
  • Gastrointestinal bleeding: Hematemesis or melena from ulcer erosion.
  • Gastric outlet obstruction: Persistent vomiting and bloating due to ulcer scarring.
  • Metastatic symptoms: If the tumor spreads to the liver or lymph nodes, patients may experience abdominal fullness, jaundice, or right‑upper‑quadrant pain.
  • MEN‑1 manifestations (if present): Hyperparathyroidism (kidney stones, bone pain) and pituitary tumors (headaches, vision changes).

Causes and Risk Factors

Malignant ZES is fundamentally a neoplastic process.

  • Gastrinomas: Typically arise in the duodenum (≈60 %) or pancreas (≈30 %). The remaining 10 % are ectopic.
  • Genetic predisposition: MEN‑1 gene mutations dramatically increase risk; patients with MEN‑1 develop multiple gastrinomas, often malignant.
  • Family history: First‑degree relatives of a patient with MEN‑1 or sporadic ZES have a higher likelihood of developing the disease.
  • Age and sex: Peak incidence in middle adulthood; males slightly more affected.
  • Environmental factors: No clear lifestyle or environmental triggers have been firmly linked to gastrinoma development.

Diagnosis

Diagnosing malignant ZES requires confirming hypergastrinemia, acid hypersecretion, and locating the tumor (including metastases).

Laboratory Tests

  • Fasting serum gastrin level: > 1,000 pg/mL (normal < 100 pg/mL) is highly suggestive. Values 2–5 ×  normal with low gastric pH also support the diagnosis.
    • secretin stimulation test – a rise in gastrin > 120 pg/mL after IV secretin is diagnostic, especially when baseline gastrin is < 1,000 pg/mL.3
  • Gastric pH measurement: < 2 confirms acid hypersecretion.
  • Chromogranin A (CgA): Elevated in many neuroendocrine tumors; useful for follow‑up.

Imaging Studies

  • Multiphasic CT scan (contrast‑enhanced): Detects primary and metastatic lesions; sensitivity ~70 % for gastrinomas > 2 cm.
  • MRI with diffusion‑weighted imaging: Superior for liver metastases.
  • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Gold standard for locating both primary and occult metastatic disease; sensitivity > 90 %.
  • EUS (Endoscopic ultrasound): Highly sensitive for small (< 1 cm) duodenal/pancreatic tumors and guides fine‑needle aspiration.

Pathology

If a lesion is surgically removed or biopsied, pathology confirms a well‑differentiated neuroendocrine tumor with immunohistochemical stains positive for gastrin, chromogranin A, and synaptophysin.

Staging

Staging follows the WHO 2017 NET classification and TNM system. Malignancy is defined by regional lymph node involvement or distant metastasis (Stage III–IV).

Treatment Options

Management aims to control acid hypersecretion, remove or reduce tumor burden, and monitor for recurrence.

Medical Therapy – Acid Control

  • Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses often 2–4 ×  standard, titrated to keep gastric pH > 3.
  • Histamine‑2 receptor antagonists (H2RAs): Cimetidine or ranitidine may be added for breakthrough symptoms, though PPIs are preferred.

Targeted & Systemic Therapies

  • Somatostatin analogues (SSA): Octreotide or lanreotide bind tumor receptors, reducing gastrin secretion and slowing growth. Particularly useful for unresectable or metastatic disease.
  • Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers targeted radiation; improves progression‑free survival in metastatic NETs (including gastrinomas).4
  • Cytotoxic chemotherapy: Streptozocin‑based regimens (streptozocin + 5‑FU or doxorubicin) are effective for high‑grade or rapidly progressing tumors.
  • Targeted kinase inhibitors: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are options for progressive, non‑resectable disease.

Surgical Management

  • Curative resection: Enucleation or pancreaticoduodenectomy (Whipple) for localized tumors; 5‑year survival > 80 % when complete resection is achieved.
  • Debulking surgery: Reduces tumor mass and acid load when complete removal isn’t possible.
  • Liver metastasectomy: Improves survival in selected patients with limited hepatic disease.

Other Interventions

  • Endoscopic ulcer therapy: Endoscopic hemostasis for bleeding ulcers.
  • Radiofrequency ablation (RFA) or embolization: For hepatic metastases not amenable to surgery.

Lifestyle & Supportive Measures

  • Small, frequent meals; avoid foods that stimulate acid (caffeine, alcohol, spicy foods).
  • Calcium and vitamin D supplementation if malabsorption or osteoporosis develops.
  • Regular bone density testing, especially in MEN‑1 patients.

Living with Zollinger‑Ellison Syndrome (Malignant)

Long‑term management requires a multidisciplinary team (gastroenterology, endocrinology, oncology, surgery, nutrition).

  • Medication adherence: Take PPIs exactly as prescribed; missing doses can precipitate severe ulcers.
  • Monitoring: Serum gastrin and CgA every 3–6 months; imaging (CT or MRI) annually or sooner if symptoms change.
  • Nutrition: Work with a dietitian to ensure adequate calories, protein, and fat intake; consider pancreatic enzyme supplements if steatorrhea persists.
  • Bone health: DEXA scan every 2 years; treat osteoporosis per NIH guidelines.
  • Psychosocial support: Join support groups, consider counseling; chronic disease can affect mental health.
  • Vaccinations: Hepatitis B & C screening; vaccinate against Hep B, Influenza, and COVID‑19, especially if on immunosuppressive therapy.

Prevention

Because malignant ZES is primarily a neoplastic disease, primary prevention is limited.

  • Genetic counseling: Individuals with a family history of MEN‑1 should receive genetic testing and surveillance.
  • Screening in high‑risk groups: Annual fasting gastrin levels and imaging for MEN‑1 carriers beginning in adolescence.
  • Lifestyle: Maintaining a healthy weight and avoiding tobacco may reduce overall cancer risk, though direct links to gastrinomas are unproven.

Complications

If left untreated or inadequately controlled, malignant ZES can lead to serious sequelae:

  • Refractory peptic ulcers with perforation or hemorrhage.
  • Gastric outlet obstruction requiring surgery.
  • Severe malabsorption → weight loss, protein‑energy malnutrition, electrolyte disturbances (hypokalemia, metabolic alkalosis).
  • Osteoporosis/fractures from chronic acid‑induced calcium loss.
  • Liver failure from extensive hepatic metastases.
  • Carcinoma progression leading to reduced survival; median 5‑year survival for metastatic disease is ≈30–40 % with modern therapy.5

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red) or material that looks like coffee grounds.
  • Black, tarry stools (melena) indicating gastrointestinal bleeding.
  • Profuse, watery diarrhea leading to dehydration (dry mouth, dizziness, scant urine).
  • High fever (> 38.5 °C/101 °F) with abdominal pain – possible perforated ulcer or infection.
  • Sudden weakness, fainting, or rapid heartbeat – could signal severe electrolyte imbalance.

These signs require immediate medical evaluation to prevent life‑threatening complications.

References

  1. Mayo Clinic. “Zollinger‑Ellison syndrome.” 2023. https://www.mayoclinic.org/…
  2. American Journal of Gastroenterology. “Epidemiology of Gastrinomas and ZES.” 2022;117(5):1023‑1030.
  3. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” Updated 2021. https://www.niddk.nih.gov/…
  4. NEJM. “Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.” 2020;383:1646‑1656.
  5. Cleveland Clinic. “Neuroendocrine Tumors: Prognosis and Survival.” 2024. https://my.clevelandclinic.org/…
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References